In this study, the authors show that the expression level of both tested miR-23b molecules did not show any significant differences between patients suffering from myositis and control cohort. Furthermore, they did not find any difference in miR-23b (or miR-23b*) expression between DM and PM patients.
They hypothesize, that the regulative role of miR-23b in the development of myositis is not taking place in PMBCs, but the involvement of this system in the local inflammatory process within the inflamed myositis muscle tissue is not excluded